ID   G6PD_HUMAN              Reviewed;         515 AA.
AC   P11413; D3DWX9; Q16000; Q16765; Q8IU70; Q8IU88; Q8IUA6; Q96PQ2;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 226.
DE   RecName: Full=Glucose-6-phosphate 1-dehydrogenase;
DE            Short=G6PD;
DE            EC=1.1.1.49;
GN   Name=G6PD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=3515319; DOI=10.1093/nar/14.6.2511;
RA   Persico M.G., Viglietto G., Martini G., Toniolo D., Paonessa G.,
RA   Moscatelli C., Dono R., Vulliamy T.J., Luzzatto L., D'Urso M.;
RT   "Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA
RT   clones: primary structure of the protein and unusual 5' non-coding
RT   region.";
RL   Nucleic Acids Res. 14:2511-2522(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2428611;
RA   Martini G., Toniolo D., Vulliamy T., Luzzatto L., Dono R.,
RA   Viglietto G., Paonessa G., D'Urso M., Persico M.G.;
RT   "Structural analysis of the X-linked gene encoding human glucose 6-
RT   phosphate dehydrogenase.";
RL   EMBO J. 5:1849-1855(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), PARTIAL NUCLEOTIDE
RP   SEQUENCE [MRNA] (ISOFORM LONG), VARIANT NSHA MET-68, AND VARIANT
RP   ASP-126.
RX   PubMed=2836867; DOI=10.1073/pnas.85.11.3951;
RA   Hirono A., Beutler E.;
RT   "Molecular cloning and nucleotide sequence of cDNA for human glucose-
RT   6-phosphate dehydrogenase variant A(-).";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:3951-3954(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT NSHA MET-68, AND VARIANT
RP   ASP-126.
RX   PubMed=1889820; DOI=10.1016/0888-7543(91)90465-Q;
RA   Chen E.Y., Cheng A., Lee A., Kuang W., Hillier L., Green P.,
RA   Schlessinger D., Ciccodicola A., D'Urso M.;
RT   "Sequence of human glucose-6-phosphate dehydrogenase cloned in
RT   plasmids and a yeast artificial chromosome.";
RL   Genomics 10:792-800(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT NSHA MET-68, AND VARIANT
RP   ASP-126.
RX   PubMed=8733135; DOI=10.1093/hmg/5.5.659;
RA   Chen E.Y., Zollo M., Mazzarella R.A., Ciccodicola A., Chen C.-N.,
RA   Zuo L., Heiner C., Burough F.W., Ripetto M., Schlessinger D.,
RA   D'Urso M.;
RT   "Long-range sequence analysis in Xq28: thirteen known and six
RT   candidate genes in 219.4 kb of high GC DNA between the RCP/GCP and
RT   G6PD loci.";
RL   Hum. Mol. Genet. 5:659-668(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-71.
RX   PubMed=2758468; DOI=10.1016/0092-8674(89)90440-6;
RA   Kanno H., Huang I.Y., Kan Y.W., Yoshida A.;
RT   "Two structural genes on different chromosomes are required for
RT   encoding the major subunit of human red cell glucose-6-phosphate
RT   dehydrogenase.";
RL   Cell 58:595-606(1989).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-71 (ISOFORM 3).
RX   PubMed=8466644; DOI=10.1089/dna.1993.12.209;
RA   Kanno H., Kondoh T., Yoshida A.;
RT   "5' structure and expression of human glucose-6-phosphate
RT   dehydrogenase mRNA.";
RL   DNA Cell Biol. 12:209-215(1993).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-15.
RX   PubMed=1874446; DOI=10.1016/0378-1119(91)90078-P;
RA   Toniolo D., Filippi M., Dono R., Lettieri T., Martini G.;
RT   "The CpG island in the 5' region of the G6PD gene of man and mouse.";
RL   Gene 102:197-203(1991).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-9.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 30-34, AND VARIANT NSHA ARG-32.
RX   PubMed=1945893; DOI=10.1093/nar/19.21.6056;
RA   Chao L.T., Du C.S., Louie E., Zuo L., Chen E., Lubin B., Chiu D.T.;
RT   "A to G substitution identified in exon 2 of the G6PD gene among G6PD
RT   deficient Chinese.";
RL   Nucleic Acids Res. 19:6056-6056(1991).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 41-515 (ISOFORM SHORT), VARIANT
RP   NSHA MET-68, AND VARIANT ASP-126.
RX   PubMed=12524354;
RA   Saunders M.A., Hammer M.F., Nachman M.W.;
RT   "Nucleotide variability at G6pd and the signature of malarial
RT   selection in humans.";
RL   Genetics 162:1849-1861(2002).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 154-515 (ISOFORM SHORT).
RX   PubMed=3012556; DOI=10.1073/pnas.83.12.4157;
RA   Takizawa T., Huang I.-Y., Ikuta T., Yoshida A.;
RT   "Human glucose-6-phosphate dehydrogenase: primary structure and cDNA
RT   cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:4157-4161(1986).
RN   [16]
RP   PROTEIN SEQUENCE OF 199-215.
RX   PubMed=3126064; DOI=10.1111/j.1432-1033.1988.tb13815.x;
RA   Camardella L., Caruso C., Rutigliano B., Romano M., di Prisco G.,
RA   Descalzi-Cancedda F.;
RT   "Human erythrocyte glucose-6-phosphate dehydrogenase. Identification
RT   of a reactive lysyl residue labelled with pyridoxal 5'-phosphate.";
RL   Eur. J. Biochem. 171:485-489(1988).
RN   [17]
RP   PROTEIN SEQUENCE OF 509-515.
RX   PubMed=6696761; DOI=10.1016/0006-291X(84)91105-7;
RA   Descalzi-Cancedda F., Caruso C., Romano M., di Prisco G.,
RA   Camardella L.;
RT   "Amino acid sequence of the carboxy-terminal end of human erythrocyte
RT   glucose-6-phosphate dehydrogenase.";
RL   Biochem. Biophys. Res. Commun. 118:332-338(1984).
RN   [18]
RP   ALTERNATIVE SPLICING.
RX   PubMed=2910917; DOI=10.1172/JCI113881;
RA   Hirono A., Beutler E.;
RT   "Alternative splicing of human glucose-6-phosphate dehydrogenase
RT   messenger RNA in different tissues.";
RL   J. Clin. Invest. 83:343-346(1989).
RN   [19]
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=7857286; DOI=10.1006/bbrc.1995.1192;
RA   Camardella L., Damonte G., Carratore V., Benatti U., Tonetti M.,
RA   Moneti G.;
RT   "Glucose 6-phosphate dehydrogenase from human erythrocytes:
RT   identification of N-acetyl-alanine at the N-terminus of the mature
RT   protein.";
RL   Biochem. Biophys. Res. Commun. 207:331-338(1995).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-89; LYS-171; LYS-403;
RP   LYS-432 AND LYS-497, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   REVIEW.
RX   PubMed=22431005; DOI=10.1002/iub.1017;
RA   Stanton R.C.;
RT   "Glucose-6-phosphate dehydrogenase, NADPH, and cell survival.";
RL   IUBMB Life 64:362-369(2012).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8; THR-10 AND TYR-503,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   FUNCTION, ACETYLATION AT LYS-403 BY ELP3, DEACETYLATION AT LYS-403 BY
RP   SIRT2, INTERACTION WITH SIRT2, MUTAGENESIS OF LYS-171; LYS-386 AND
RP   LYS-403, AND SUBUNIT.
RX   PubMed=24769394; DOI=10.1002/embj.201387224;
RA   Wang Y.P., Zhou L.S., Zhao Y.Z., Wang S.W., Chen L.L., Liu L.X.,
RA   Ling Z.Q., Hu F.J., Sun Y.P., Zhang J.Y., Yang C., Yang Y., Xiong Y.,
RA   Guan K.L., Ye D.;
RT   "Regulation of G6PD acetylation by KAT9/SIRT2 modulates NADPH
RT   homeostasis and cell survival during oxidative stress.";
RL   EMBO J. 33:1304-1320(2014).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF VARIANT CANTON IN COMPLEX
RP   WITH NADP, AND SUBUNIT.
RX   PubMed=10745013; DOI=10.1016/S0969-2126(00)00104-0;
RA   Au S.W., Gover S., Lam V.M., Adams M.J.;
RT   "Human glucose-6-phosphate dehydrogenase: the crystal structure
RT   reveals a structural NADP(+) molecule and provides insights into
RT   enzyme deficiency.";
RL   Structure 8:293-303(2000).
RN   [30]
RP   REVIEW ON VARIANTS.
RX   PubMed=8364584; DOI=10.1002/humu.1380020302;
RA   Vulliamy T., Beutler E., Luzzatto L.;
RT   "Variants of glucose-6-phosphate dehydrogenase are due to missense
RT   mutations spread throughout the coding region of the gene.";
RL   Hum. Mutat. 2:159-167(1993).
RN   [31]
RP   REVIEW ON VARIANTS.
RX   PubMed=11857737; DOI=10.1002/humu.10036;
RA   Kwok C.J., Martin A.C., Au S.W., Lam V.M.;
RT   "G6PDdb, an integrated database of glucose-6-phosphate dehydrogenase
RT   (G6PD) mutations.";
RL   Hum. Mutat. 19:217-224(2002).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 28-514 IN COMPLEX WITH NADP
RP   AND GLUCOSE 6-PHOSPHATE, FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=15858258; DOI=10.1107/S0907444905002350;
RA   Kotaka M., Gover S., Vandeputte-Rutten L., Au S.W., Lam V.M.,
RA   Adams M.J.;
RT   "Structural studies of glucose-6-phosphate and NADP+ binding to human
RT   glucose-6-phosphate dehydrogenase.";
RL   Acta Crystallogr. D 61:495-504(2005).
RN   [33]
RP   VARIANT ASP-126.
RX   PubMed=3446582; DOI=10.1016/0888-7543(87)90048-6;
RA   Takizawa T., Yoneyama Y., Miwa S., Yoshida A.;
RT   "A single nucleotide base transition is the basis of the common human
RT   glucose-6-phosphate dehydrogenase variant A (+).";
RL   Genomics 1:228-231(1987).
RN   [34]
RP   VARIANTS.
RX   PubMed=3393536; DOI=10.1073/pnas.85.14.5171;
RA   Vulliamy T.J., D'Urso M., Battistuzzi G., Estrada M., Foulkes N.S.,
RA   Martini G., Calabro V., Poggi V., Giordano R., Town M., Luzzatto L.,
RA   Persico M.G.;
RT   "Diverse point mutations in the human glucose-6-phosphate
RT   dehydrogenase gene cause enzyme deficiency and mild or severe
RT   hemolytic anemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:5171-5175(1988).
RN   [35]
RP   VARIANTS NSHA PHE-188 AND HIS-282.
RX   PubMed=2912069;
RA   de Vita G., Alcalay M., Sampietro M., Cappelini M.D., Fiorelli G.,
RA   Toniolo D.;
RT   "Two point mutations are responsible for G6PD polymorphism in
RT   Sardinia.";
RL   Am. J. Hum. Genet. 44:233-240(1989).
RN   [36]
RP   VARIANTS NSHA GLN-227; SER-353; CYS-387; LEU-394; ASP-410 AND PRO-439.
RX   PubMed=1611091;
RA   Beutler E., Westwood B., Prchal J.T., Vaca C.S., Bartsocas C.S.,
RA   Baronciani L.;
RT   "New glucose-6-phosphate dehydrogenase mutations from various ethnic
RT   groups.";
RL   Blood 80:255-256(1992).
RN   [37]
RP   VARIANT NSHA HIS-393.
RX   PubMed=1536798; DOI=10.1111/j.1365-2141.1992.tb06409.x;
RA   Filosa S., Calabro V., Vallone D., Poggi V., Mason P., Pagnini D.,
RA   Alfinito F., Rotoli B., Martini G., Luzzatto L., Battistuzzi G.;
RT   "Molecular basis of chronic non-spherocytic haemolytic anaemia: a new
RT   G6PD variant (393arg-to-his) with abnormal K(m) G6P and marked in vivo
RT   instability.";
RL   Br. J. Haematol. 80:111-116(1992).
RN   [38]
RP   VARIANT NSHA CYS-454.
RX   PubMed=1303180; DOI=10.1093/hmg/1.3.205;
RA   Perng L.-I., Chiou S.-S., Liu T.-C., Chang J.-G.;
RT   "A novel C to T substitution at nucleotide 1360 of cDNA which
RT   abolishes a natural Hha I site accounts for a new G6PD deficiency gene
RT   in Chinese.";
RL   Hum. Mol. Genet. 1:205-205(1992).
RN   [39]
RP   VARIANT NSHA LYS-317.
RX   PubMed=1303182; DOI=10.1093/hmg/1.3.209;
RA   Ahluwalia A., Corcoran C.M., Vulliamy T.J., Ishwad C.S., Naidu J.M.,
RA   Stevens D.J., Mason P.J., Luzzatto L.;
RT   "G6PD Kalyan and G6PD Kerala; two deficient variants in India caused
RT   by the same 317 Glu-->Lys mutation.";
RL   Hum. Mol. Genet. 1:209-210(1992).
RN   [40]
RP   VARIANT NSHA THR-48.
RX   PubMed=8490627; DOI=10.1093/hmg/2.1.81;
RA   Nafa K., Reghis A., Osmani N., Baghli L., Benabadji M., Kaplan J.-C.,
RA   Vulliamy T.J., Luzzatto L.;
RT   "G6PD Aures: a new mutation (48 Ile-->Thr) causing mild G6PD
RT   deficiency is associated with favism.";
RL   Hum. Mol. Genet. 2:81-82(1993).
RN   [41]
RP   VARIANT NSHA GLY-176.
RX   PubMed=8193373;
RA   Hirono A., Miwa S., Fujii H., Ishida F., Yamada K., Kubota K.;
RT   "Molecular study of eight Japanese cases of glucose-6-phosphate
RT   dehydrogenase deficiency by nonradioisotopic single-strand
RT   conformation polymorphism analysis.";
RL   Blood 83:3363-3368(1994).
RN   [42]
RP   VARIANT NSHA LEU-396.
RX   PubMed=7959695; DOI=10.1007/BF00211027;
RA   Filosa S., Cai W., Galanello R., Cao A., de Mattia D., Schettini F.,
RA   Martini G.;
RT   "A novel single-base mutation in the glucose 6-phosphate dehydrogenase
RT   gene is associated with chronic non-spherocytic haemolytic anaemia.";
RL   Hum. Genet. 94:560-562(1994).
RN   [43]
RP   VARIANTS NAMORU; VANUA LAVA; NAONE AND UNION.
RX   PubMed=7825590;
RA   Ganczakowski M., Town M., Bowden D.K., Vulliamy T.J., Kaneko A.,
RA   Clegg J.B., Weatherall D.J., Luzzatto L.;
RT   "Multiple glucose 6-phosphate dehydrogenase-deficient variants
RT   correlate with malaria endemicity in the Vanuatu archipelago
RT   (southwestern Pacific).";
RL   Am. J. Hum. Genet. 56:294-301(1995).
RN   [44]
RP   VARIANT NSHA GLY-44.
RX   PubMed=8533762;
RA   Kaeda J.S., Chhotray G.P., Ranjit M.R., Bautista J.M., Reddy P.H.,
RA   Stevens D., Naidu J.M., Britt R.P., Vulliamy T.J., Luzzatto L.,
RA   Mason P.J.;
RT   "A new glucose-6-phosphate dehydrogenase variant, G6PD Orissa (44
RT   Ala-->Gly), is the major polymorphic variant in tribal populations in
RT   India.";
RL   Am. J. Hum. Genet. 57:1335-1341(1995).
RN   [45]
RP   VARIANTS NSHA PRO-75; ASP-163; LYS-274 AND PHE-278.
RX   PubMed=7858267;
RA   Mason P.J., Sonati M.F., Macdonald D., Lanza C., Busutil D., Town M.,
RA   Corcoran C.M., Kaeda J.S., Stevens D.J., Al-Ismail S., Altay C.,
RA   Hatton C., Lewis D.S., McMullin M.F., Meloni T., Paul B., Pippard M.,
RA   Prentice A.G., Vulliamy T.J., Luzzatto L.;
RT   "New glucose-6-phosphate dehydrogenase mutations associated with
RT   chronic anemia.";
RL   Blood 85:1377-1380(1995).
RN   [46]
RP   VARIANT NSHA CYS-387, AND VARIANT ASP-126.
RX   PubMed=9452072;
RA   Vlachos A., Westwood B., Lipton J.M., Beutler E.;
RT   "G6PD Mount Sinai: a new severe hemolytic variant characterized by
RT   dual mutations at nucleotides 376G and 1159T (N126D).";
RL   Hum. Mutat. Suppl. 1:S154-S155(1998).
RN   [47]
RP   VARIANT SINNAI LEU-12.
RX   PubMed=10627140;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<72::AID-HUMU19>3.0.CO;2-T;
RA   Galanello R., Loi D., Sollaino C., Dessi S., Cao A., Melis M.A.;
RT   "A new glucose 6 phosphate dehydrogenase variant, G6PD Sinnai (34
RT   G->T).";
RL   Hum. Mutat. 12:72-73(1998).
RN   [48]
RP   VARIANT REHOVOT HIS-322.
RX   PubMed=11112389; DOI=10.1006/bcmd.2000.0334;
RA   Iancovici-Kidon M., Sthoeger D., Abrahamov A., Volach B., Beutler E.,
RA   Gelbart T., Barak Y.;
RT   "A new exon 9 glucose-6-phosphate dehydrogenase mutation (G6PD
RT   'Rehovot') in a Jewish Ethiopian family with variable phenotypes.";
RL   Blood Cells Mol. Dis. 26:567-571(2000).
RN   [49]
RP   ASSOCIATION OF VARIANT NSHA SER-163 WITH REDUCED DENSITY OF PLASMODIUM
RP   VIVAX.
RX   PubMed=20007901; DOI=10.1126/science.1178849;
RA   Louicharoen C., Patin E., Paul R., Nuchprayoon I., Witoonpanich B.,
RA   Peerapittayamongkol C., Casademont I., Sura T., Laird N.M.,
RA   Singhasivanon P., Quintana-Murci L., Sakuntabhai A.;
RT   "Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax
RT   density in Southeast Asians.";
RL   Science 326:1546-1549(2009).
RN   [50]
RP   VARIANT NSHA SER-198, AND CHARACTERIZATION OF VARIANT NSHA SER-198.
RX   PubMed=26479991; DOI=10.1097/MPH.0000000000000435;
RA   Warny M., Lausen B., Birgens H., Knabe N., Petersen J.;
RT   "Severe G6PD Deficiency Due to a New Missense Mutation in an Infant of
RT   Northern European Descent.";
RL   J. Pediatr. Hematol. Oncol. 37:E497-E499(2015).
RN   [51]
RP   VARIANT ASP-126.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E.,
RA   Fennell T., O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B.,
RA   Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K.,
RA   Zhao F., Zou J., Pierce-Hoffman E., Berghout J., Cooper D.N.,
RA   Deflaux N., DePristo M., Do R., Flannick J., Fromer M., Gauthier L.,
RA   Goldstein J., Gupta N., Howrigan D., Kiezun A., Kurki M.I.,
RA   Moonshine A.L., Natarajan P., Orozco L., Peloso G.M., Poplin R.,
RA   Rivas M.A., Ruano-Rubio V., Rose S.A., Ruderfer D.M., Shakir K.,
RA   Stenson P.D., Stevens C., Thomas B.P., Tiao G., Tusie-Luna M.T.,
RA   Weisburd B., Won H.H., Yu D., Altshuler D.M., Ardissino D.,
RA   Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S.,
RA   Laakso M., McCarroll S., McCarthy M.I., McGovern D., McPherson R.,
RA   Neale B.M., Palotie A., Purcell S.M., Saleheen D., Scharf J.M.,
RA   Sklar P., Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C.,
RA   Wilson J.G., Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
CC   -!- FUNCTION: Catalyzes the rate-limiting step of the oxidative
CC       pentose-phosphate pathway, which represents a route for the
CC       dissimilation of carbohydrates besides glycolysis. The main
CC       function of this enzyme is to provide reducing power (NADPH) and
CC       pentose phosphates for fatty acid and nucleic acid synthesis.
CC       {ECO:0000269|PubMed:15858258, ECO:0000269|PubMed:24769394}.
CC   -!- CATALYTIC ACTIVITY: D-glucose 6-phosphate + NADP(+) = 6-phospho-D-
CC       glucono-1,5-lactone + NADPH. {ECO:0000269|PubMed:15858258}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.07 uM for NADP {ECO:0000269|PubMed:15858258};
CC         KM=52 uM for glucose 6-phosphate {ECO:0000269|PubMed:15858258};
CC   -!- PATHWAY: Carbohydrate degradation; pentose phosphate pathway; D-
CC       ribulose 5-phosphate from D-glucose 6-phosphate (oxidative stage):
CC       step 1/3.
CC   -!- SUBUNIT: Homotetramer; dimer of dimers. Interacts with SIRT2; the
CC       interaction is enhanced by H(2)O(2) treatment.
CC       {ECO:0000269|PubMed:10745013, ECO:0000269|PubMed:15858258,
CC       ECO:0000269|PubMed:24769394}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-4289891, EBI-4289891;
CC       P04792:HSPB1; NbExp=2; IntAct=EBI-4289891, EBI-352682;
CC       Q8IXJ6:SIRT2; NbExp=3; IntAct=EBI-4289891, EBI-477232;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Short;
CC         IsoId=P11413-1; Sequence=Displayed;
CC       Name=Long;
CC         IsoId=P11413-2; Sequence=VSP_001592;
CC       Name=3;
CC         IsoId=P11413-3; Sequence=VSP_037802;
CC         Note=Contains a phosphoserine at position 26.
CC         {ECO:0000244|PubMed:18669648};
CC   -!- TISSUE SPECIFICITY: Isoform Long is found in lymphoblasts,
CC       granulocytes and sperm.
CC   -!- PTM: Acetylated by ELP3 at Lys-403; acetylation inhibits its
CC       homodimerization and enzyme activity. Deacetylated by SIRT2 at
CC       Lys-403; deacetylation stimulates its enzyme activity.
CC       {ECO:0000269|PubMed:24769394, ECO:0000269|PubMed:7857286}.
CC   -!- POLYMORPHISM: The sequence shown is that of variant B, the most
CC       common variant.
CC   -!- DISEASE: Anemia, non-spherocytic hemolytic, due to G6PD deficiency
CC       (NSHA) [MIM:300908]: A disease characterized by G6PD deficiency,
CC       acute hemolytic anemia, fatigue, back pain, and jaundice. In most
CC       patients, the disease is triggered by an exogenous agent, such as
CC       some drugs, food, or infection. Increased unconjugated bilirubin,
CC       lactate dehydrogenase, and reticulocytosis are markers of the
CC       disorder. Although G6PD deficiency can be life-threatening, most
CC       patients are asymptomatic throughout their life.
CC       {ECO:0000269|PubMed:12524354, ECO:0000269|PubMed:1303180,
CC       ECO:0000269|PubMed:1303182, ECO:0000269|PubMed:1536798,
CC       ECO:0000269|PubMed:1611091, ECO:0000269|PubMed:1889820,
CC       ECO:0000269|PubMed:1945893, ECO:0000269|PubMed:20007901,
CC       ECO:0000269|PubMed:26479991, ECO:0000269|PubMed:2836867,
CC       ECO:0000269|PubMed:2912069, ECO:0000269|PubMed:7858267,
CC       ECO:0000269|PubMed:7959695, ECO:0000269|PubMed:8193373,
CC       ECO:0000269|PubMed:8490627, ECO:0000269|PubMed:8533762,
CC       ECO:0000269|PubMed:8733135, ECO:0000269|PubMed:9452072}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry. Deficiency of G6PD is associated with hemolytic anemia
CC       in two different situations. First, in areas in which malaria has
CC       been endemic, G6PD-deficiency alleles have reached high
CC       frequencies (1% to 50%) and deficient individuals, though
CC       essentially asymptomatic in the steady state, have a high risk of
CC       acute hemolytic attacks. Secondly, sporadic cases of G6PD
CC       deficiency occur at a very low frequencies, and they usually
CC       present a more severe phenotype. Several types of NSHA are
CC       recognized. Class-I variants are associated with severe NSHA;
CC       class-II have an activity <10% of normal; class-III have an
CC       activity of 10% to 60% of normal; class-IV have near normal
CC       activity.
CC   -!- MISCELLANEOUS: Binds two molecules of NADP. The first one is a
CC       cosubstrate (bound to the N-terminal domain), the second is bound
CC       to the C-terminal domain and functions as a structural element.
CC   -!- SIMILARITY: Belongs to the glucose-6-phosphate dehydrogenase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA63175.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=G6PDdb; Note=G6PD mutation database;
CC       URL="http://www.bioinf.org.uk/g6pd/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=G6PD";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03674; CAA27309.1; -; mRNA.
DR   EMBL; M65234; AAA63175.1; ALT_INIT; Genomic_DNA.
DR   EMBL; M26749; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M26750; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65225; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65226; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65227; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65228; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65229; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65230; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65231; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65233; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M65232; AAA63175.1; JOINED; Genomic_DNA.
DR   EMBL; M21248; AAA52500.1; -; mRNA.
DR   EMBL; M19866; AAA52501.1; -; mRNA.
DR   EMBL; X55448; CAA39089.1; -; Genomic_DNA.
DR   EMBL; L44140; AAA92653.1; -; Genomic_DNA.
DR   EMBL; AF277315; AAL27011.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72682.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72686.1; -; Genomic_DNA.
DR   EMBL; BC000337; AAH00337.1; -; mRNA.
DR   EMBL; M27940; AAA52504.1; -; mRNA.
DR   EMBL; S58359; AAB26169.1; -; mRNA.
DR   EMBL; X53815; CAA37811.1; -; Genomic_DNA.
DR   EMBL; S64462; AAB20299.1; -; Genomic_DNA.
DR   EMBL; AY158096; AAN76367.1; -; Genomic_DNA.
DR   EMBL; AY158097; AAN76368.1; -; Genomic_DNA.
DR   EMBL; AY158098; AAN76369.1; -; Genomic_DNA.
DR   EMBL; AY158099; AAN76370.1; -; Genomic_DNA.
DR   EMBL; AY158100; AAN76371.1; -; Genomic_DNA.
DR   EMBL; AY158101; AAN76372.1; -; Genomic_DNA.
DR   EMBL; AY158102; AAN76373.1; -; Genomic_DNA.
DR   EMBL; AY158103; AAN76374.1; -; Genomic_DNA.
DR   EMBL; AY158104; AAN76375.1; -; Genomic_DNA.
DR   EMBL; AY158105; AAN76376.1; -; Genomic_DNA.
DR   EMBL; AY158106; AAN76377.1; -; Genomic_DNA.
DR   EMBL; AY158107; AAN76378.1; -; Genomic_DNA.
DR   EMBL; AY158108; AAN76379.1; -; Genomic_DNA.
DR   EMBL; AY158109; AAN76380.1; -; Genomic_DNA.
DR   EMBL; AY158110; AAN76381.1; -; Genomic_DNA.
DR   EMBL; AY158111; AAN76382.1; -; Genomic_DNA.
DR   EMBL; AY158112; AAN76383.1; -; Genomic_DNA.
DR   EMBL; AY158113; AAN76384.1; -; Genomic_DNA.
DR   EMBL; AY158114; AAN76385.1; -; Genomic_DNA.
DR   EMBL; AY158115; AAN76386.1; -; Genomic_DNA.
DR   EMBL; AY158116; AAN76387.1; -; Genomic_DNA.
DR   EMBL; AY158117; AAN76388.1; -; Genomic_DNA.
DR   EMBL; AY158118; AAN76389.1; -; Genomic_DNA.
DR   EMBL; AY158119; AAN76390.1; -; Genomic_DNA.
DR   EMBL; AY158120; AAN76391.1; -; Genomic_DNA.
DR   EMBL; AY158121; AAN76392.1; -; Genomic_DNA.
DR   EMBL; AY158122; AAN76393.1; -; Genomic_DNA.
DR   EMBL; AY158123; AAN76394.1; -; Genomic_DNA.
DR   EMBL; AY158124; AAN76395.1; -; Genomic_DNA.
DR   EMBL; AY158125; AAN76396.1; -; Genomic_DNA.
DR   EMBL; AY158126; AAN76397.1; -; Genomic_DNA.
DR   EMBL; AY158127; AAN76398.1; -; Genomic_DNA.
DR   EMBL; AY158128; AAN76399.1; -; Genomic_DNA.
DR   EMBL; AY158129; AAN76400.1; -; Genomic_DNA.
DR   EMBL; AY158130; AAN76401.1; -; Genomic_DNA.
DR   EMBL; AY158131; AAN76402.1; -; Genomic_DNA.
DR   EMBL; AY158132; AAN76403.1; -; Genomic_DNA.
DR   EMBL; AY158133; AAN76404.1; -; Genomic_DNA.
DR   EMBL; AY158134; AAN76405.1; -; Genomic_DNA.
DR   EMBL; AY158135; AAN76406.1; -; Genomic_DNA.
DR   EMBL; AY158136; AAN76407.1; -; Genomic_DNA.
DR   EMBL; AY158137; AAN76408.1; -; Genomic_DNA.
DR   EMBL; AY158138; AAN76409.1; -; Genomic_DNA.
DR   EMBL; AY158139; AAN76410.1; -; Genomic_DNA.
DR   EMBL; AY158140; AAN76411.1; -; Genomic_DNA.
DR   EMBL; AY158141; AAN76412.1; -; Genomic_DNA.
DR   EMBL; AY158142; AAN76413.1; -; Genomic_DNA.
DR   EMBL; M12996; AAA52499.1; -; mRNA.
DR   EMBL; M23423; AAB59390.1; -; Genomic_DNA.
DR   CCDS; CCDS14756.2; -. [P11413-3]
DR   CCDS; CCDS44023.1; -. [P11413-1]
DR   PIR; A40309; DEHUG6.
DR   RefSeq; NP_000393.4; NM_000402.4. [P11413-3]
DR   RefSeq; NP_001035810.1; NM_001042351.2. [P11413-1]
DR   UniGene; Hs.461047; -.
DR   UniGene; Hs.684904; -.
DR   PDB; 1QKI; X-ray; 3.00 A; A/B/C/D/E/F/G/H=2-515.
DR   PDB; 2BH9; X-ray; 2.50 A; A=27-515.
DR   PDB; 2BHL; X-ray; 2.90 A; A/B=28-515.
DR   PDBsum; 1QKI; -.
DR   PDBsum; 2BH9; -.
DR   PDBsum; 2BHL; -.
DR   ProteinModelPortal; P11413; -.
DR   SMR; P11413; -.
DR   BioGrid; 108814; 65.
DR   IntAct; P11413; 6.
DR   MINT; MINT-4716941; -.
DR   STRING; 9606.ENSP00000377192; -.
DR   BindingDB; P11413; -.
DR   ChEMBL; CHEMBL5347; -.
DR   DrugBank; DB05107; 16-Bromoepiandrosterone.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB03085; Hydroxyacetic Acid.
DR   iPTMnet; P11413; -.
DR   PhosphoSitePlus; P11413; -.
DR   SwissPalm; P11413; -.
DR   DMDM; 116242483; -.
DR   REPRODUCTION-2DPAGE; IPI00289800; -.
DR   SWISS-2DPAGE; P11413; -.
DR   EPD; P11413; -.
DR   MaxQB; P11413; -.
DR   PaxDb; P11413; -.
DR   PeptideAtlas; P11413; -.
DR   PRIDE; P11413; -.
DR   DNASU; 2539; -.
DR   Ensembl; ENST00000369620; ENSP00000358633; ENSG00000160211. [P11413-2]
DR   Ensembl; ENST00000393562; ENSP00000377192; ENSG00000160211. [P11413-3]
DR   Ensembl; ENST00000393564; ENSP00000377194; ENSG00000160211. [P11413-1]
DR   Ensembl; ENST00000621232; ENSP00000483686; ENSG00000160211. [P11413-1]
DR   GeneID; 2539; -.
DR   KEGG; hsa:2539; -.
DR   UCSC; uc004flx.3; human. [P11413-1]
DR   CTD; 2539; -.
DR   DisGeNET; 2539; -.
DR   GeneCards; G6PD; -.
DR   HGNC; HGNC:4057; G6PD.
DR   HPA; HPA000247; -.
DR   HPA; HPA000834; -.
DR   MalaCards; G6PD; -.
DR   MIM; 300908; phenotype.
DR   MIM; 305900; gene.
DR   neXtProt; NX_P11413; -.
DR   OpenTargets; ENSG00000160211; -.
DR   Orphanet; 362; Glucose-6-phosphate-dehydrogenase deficiency.
DR   PharmGKB; PA28469; -.
DR   eggNOG; KOG0563; Eukaryota.
DR   eggNOG; COG0364; LUCA.
DR   GeneTree; ENSGT00530000063435; -.
DR   HOVERGEN; HBG000856; -.
DR   InParanoid; P11413; -.
DR   KO; K00036; -.
DR   OMA; TIFEPIW; -.
DR   OrthoDB; EOG091G06FN; -.
DR   PhylomeDB; P11413; -.
DR   TreeFam; TF300584; -.
DR   BioCyc; MetaCyc:HS08467-MONOMER; -.
DR   BRENDA; 1.1.1.49; 2681.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-71336; Pentose phosphate pathway (hexose monophosphate shunt).
DR   SABIO-RK; P11413; -.
DR   SIGNOR; P11413; -.
DR   UniPathway; UPA00115; UER00408.
DR   ChiTaRS; G6PD; human.
DR   EvolutionaryTrace; P11413; -.
DR   GeneWiki; Glucose-6-phosphate_dehydrogenase; -.
DR   GenomeRNAi; 2539; -.
DR   PRO; PR:P11413; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000160211; -.
DR   CleanEx; HS_G6PD; -.
DR   ExpressionAtlas; P11413; baseline and differential.
DR   Genevisible; P11413; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005536; F:glucose binding; IDA:BHF-UCL.
DR   GO; GO:0004345; F:glucose-6-phosphate dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0050661; F:NADP binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:BHF-UCL.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0043249; P:erythrocyte maturation; IMP:BHF-UCL.
DR   GO; GO:0051156; P:glucose 6-phosphate metabolic process; IDA:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006749; P:glutathione metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:BHF-UCL.
DR   GO; GO:0006739; P:NADP metabolic process; IDA:UniProtKB.
DR   GO; GO:0006740; P:NADPH regeneration; IMP:BHF-UCL.
DR   GO; GO:0061052; P:negative regulation of cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0010734; P:negative regulation of protein glutathionylation; IMP:BHF-UCL.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; IMP:BHF-UCL.
DR   GO; GO:0019322; P:pentose biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006098; P:pentose-phosphate shunt; IDA:BHF-UCL.
DR   GO; GO:0009051; P:pentose-phosphate shunt, oxidative branch; IMP:BHF-UCL.
DR   GO; GO:1904879; P:positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel; IEA:Ensembl.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0010041; P:response to iron(III) ion; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0046390; P:ribose phosphate biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   HAMAP; MF_00966; G6PD; 1.
DR   InterPro; IPR001282; G6P_DH.
DR   InterPro; IPR019796; G6P_DH_AS.
DR   InterPro; IPR022675; G6P_DH_C.
DR   InterPro; IPR022674; G6P_DH_NAD-bd.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   PANTHER; PTHR23429; PTHR23429; 1.
DR   Pfam; PF02781; G6PD_C; 1.
DR   Pfam; PF00479; G6PD_N; 1.
DR   PIRSF; PIRSF000110; G6PD; 1.
DR   PRINTS; PR00079; G6PDHDRGNASE.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00871; zwf; 1.
DR   PROSITE; PS00069; G6P_DEHYDROGENASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Carbohydrate metabolism; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glucose metabolism; Hereditary hemolytic anemia;
KW   NADP; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:7857286}.
FT   CHAIN         2    515       Glucose-6-phosphate 1-dehydrogenase.
FT                                /FTId=PRO_0000068083.
FT   NP_BIND      38     45       NADP 1. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   NP_BIND     401    403       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   NP_BIND     421    423       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   REGION      201    205       Substrate binding.
FT   ACT_SITE    263    263       Proton acceptor. {ECO:0000250}.
FT   BINDING      72     72       NADP 1. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     147    147       NADP 1. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     171    171       NADP 1; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     171    171       Substrate.
FT   BINDING     239    239       Substrate.
FT   BINDING     258    258       Substrate.
FT   BINDING     357    357       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     360    360       Substrate.
FT   BINDING     365    365       Substrate.
FT   BINDING     366    366       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     370    370       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     393    393       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     395    395       Substrate.
FT   BINDING     487    487       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     503    503       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   BINDING     509    509       NADP 2. {ECO:0000269|PubMed:10745013,
FT                                ECO:0000269|PubMed:15858258}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:7857286}.
FT   MOD_RES       8      8       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      10     10       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      89     89       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     171    171       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     403    403       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:24769394}.
FT   MOD_RES     432    432       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     497    497       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     503    503       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1      1       M -> MGRRGSAPGNGRTLRGCERGGRRRRSADSVM (in
FT                                isoform 3). {ECO:0000303|PubMed:8466644}.
FT                                /FTId=VSP_037802.
FT   VAR_SEQ     257    257       R -> RGPGRQGGSGSESCSLSLGSLVWGPHALEPGEQGGE
FT                                LRRALASSVPR (in isoform Long).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001592.
FT   VARIANT      12     12       V -> L (in Sinnai).
FT                                {ECO:0000269|PubMed:10627140}.
FT                                /FTId=VAR_002450.
FT   VARIANT      32     32       H -> R (in NSHA; Gahoe; class III;
FT                                frequent in Chinese; dbSNP:rs137852340).
FT                                {ECO:0000269|PubMed:1945893}.
FT                                /FTId=VAR_002451.
FT   VARIANT      35     35       Missing (in NSHA; Sunderland; class I).
FT                                /FTId=VAR_002452.
FT   VARIANT      44     44       A -> G (in NSHA; Orissa; class III;
FT                                frequent in Indian tribal populations;
FT                                dbSNP:rs78478128).
FT                                {ECO:0000269|PubMed:8533762}.
FT                                /FTId=VAR_002453.
FT   VARIANT      48     48       I -> T (in NSHA; Aures; class II;
FT                                dbSNP:rs76645461).
FT                                {ECO:0000269|PubMed:8490627}.
FT                                /FTId=VAR_002454.
FT   VARIANT      58     58       D -> N (in NSHA; Metaponto; class III;
FT                                dbSNP:rs137852315).
FT                                /FTId=VAR_002455.
FT   VARIANT      68     68       V -> M (in NSHA; A(-) type I; class III;
FT                                frequent in African population;
FT                                dbSNP:rs1050828).
FT                                {ECO:0000269|PubMed:12524354,
FT                                ECO:0000269|PubMed:1889820,
FT                                ECO:0000269|PubMed:2836867,
FT                                ECO:0000269|PubMed:8733135}.
FT                                /FTId=VAR_002456.
FT   VARIANT      70     70       Y -> H (in NSHA; Namoru; 4% activity;
FT                                dbSNP:rs137852349).
FT                                /FTId=VAR_002457.
FT   VARIANT      75     75       L -> P (in NSHA; Swansea; class I).
FT                                {ECO:0000269|PubMed:7858267}.
FT                                /FTId=VAR_002458.
FT   VARIANT      81     81       R -> C (in NSHA; Konan/Ube; class III;
FT                                dbSNP:rs138687036).
FT                                /FTId=VAR_002460.
FT   VARIANT      81     81       R -> H (in NSHA; Lagosanto; class III;
FT                                dbSNP:rs782308266).
FT                                /FTId=VAR_002459.
FT   VARIANT     106    106       S -> C (in NSHA; Vancouver; class I;
FT                                dbSNP:rs267606835).
FT                                /FTId=VAR_002461.
FT   VARIANT     126    126       N -> D (polymorphism; found in Santa
FT                                Maria and Mount Sinai; associated with C-
FT                                387 in Mount Sinai; class IV and class I;
FT                                dbSNP:rs1050829).
FT                                {ECO:0000269|PubMed:12524354,
FT                                ECO:0000269|PubMed:1889820,
FT                                ECO:0000269|PubMed:27535533,
FT                                ECO:0000269|PubMed:2836867,
FT                                ECO:0000269|PubMed:3446582,
FT                                ECO:0000269|PubMed:8733135,
FT                                ECO:0000269|PubMed:9452072}.
FT                                /FTId=VAR_002462.
FT   VARIANT     128    128       L -> P (in NSHA; Vanua Lava; 4% activity;
FT                                dbSNP:rs78365220).
FT                                /FTId=VAR_002463.
FT   VARIANT     131    131       G -> V (in Chinese-4; dbSNP:rs137852341).
FT                                /FTId=VAR_002464.
FT   VARIANT     156    156       E -> K (in NSHA; Ilesha; class III;
FT                                dbSNP:rs137852313).
FT                                /FTId=VAR_002465.
FT   VARIANT     163    163       G -> D (in NSHA; Plymouth; class I).
FT                                {ECO:0000269|PubMed:7858267}.
FT                                /FTId=VAR_002467.
FT   VARIANT     163    163       G -> S (in NSHA; Mahidol; class III;
FT                                associated with reduced density of
FT                                Plasmodium vivax but not Plasmodium
FT                                falciparum in Southeast Asians; reduced
FT                                activity; dbSNP:rs137852314).
FT                                /FTId=VAR_002466.
FT   VARIANT     165    165       N -> D (in NSHA; Chinese-3; class II;
FT                                dbSNP:rs137852331).
FT                                /FTId=VAR_002468.
FT   VARIANT     166    166       R -> H (in NSHA; Naone; 1% activity).
FT                                /FTId=VAR_002469.
FT   VARIANT     176    176       D -> G (in NSHA; Shinshu; class I).
FT                                {ECO:0000269|PubMed:8193373}.
FT                                /FTId=VAR_002470.
FT   VARIANT     181    181       D -> V (in NSHA; Santa Maria; class I;
FT                                dbSNP:rs5030872).
FT                                /FTId=VAR_002471.
FT   VARIANT     182    182       R -> W (in NSHA; Vancouver; class I;
FT                                dbSNP:rs267606836).
FT                                /FTId=VAR_002472.
FT   VARIANT     188    188       S -> F (in NSHA; Sassari/Cagliari; class
FT                                II; frequent in the Mediterranean;
FT                                dbSNP:rs5030868).
FT                                {ECO:0000269|PubMed:2912069}.
FT                                /FTId=VAR_002473.
FT   VARIANT     198    198       R -> C (in NSHA; Coimbra; class II;
FT                                dbSNP:rs137852330).
FT                                /FTId=VAR_002474.
FT   VARIANT     198    198       R -> P (in NSHA; Santiago; class I;
FT                                dbSNP:rs137852332).
FT                                /FTId=VAR_002475.
FT   VARIANT     198    198       R -> S (in NSHA; Herlev; no
FT                                glucoshosphate dehydrogenase activity).
FT                                {ECO:0000269|PubMed:26479991}.
FT                                /FTId=VAR_075555.
FT   VARIANT     212    212       M -> V (in NSHA; Sibari; class III;
FT                                dbSNP:rs782754619).
FT                                /FTId=VAR_002476.
FT   VARIANT     213    213       V -> L (in NSHA; Minnesota; class I;
FT                                dbSNP:rs137852326).
FT                                /FTId=VAR_002477.
FT   VARIANT     216    216       F -> L (in NSHA; Harilaou; class I;
FT                                dbSNP:rs137852319).
FT                                /FTId=VAR_002478.
FT   VARIANT     227    227       R -> L (in NSHA; A- type 2; class III;
FT                                dbSNP:rs137852328).
FT                                /FTId=VAR_002480.
FT   VARIANT     227    227       R -> Q (in NSHA; Mexico City; class III;
FT                                dbSNP:rs137852328).
FT                                {ECO:0000269|PubMed:1611091}.
FT                                /FTId=VAR_002479.
FT   VARIANT     242    243       Missing (in NSHA; Stonybrook; class I).
FT                                /FTId=VAR_002481.
FT   VARIANT     257    257       R -> G (in NSHA; Wayne; class I).
FT                                /FTId=VAR_002482.
FT   VARIANT     274    274       E -> K (in NSHA; Corum; class I).
FT                                {ECO:0000269|PubMed:7858267}.
FT                                /FTId=VAR_002483.
FT   VARIANT     278    278       S -> F (in NSHA; Wexham; class I).
FT                                {ECO:0000269|PubMed:7858267}.
FT                                /FTId=VAR_002484.
FT   VARIANT     279    279       T -> S (in NSHA; Chinese-1; class II).
FT                                /FTId=VAR_002485.
FT   VARIANT     282    282       D -> H (in NSHA; Seattle; class III;
FT                                dbSNP:rs137852318).
FT                                {ECO:0000269|PubMed:2912069}.
FT                                /FTId=VAR_002486.
FT   VARIANT     285    285       R -> H (in NSHA; Montalbano; class III;
FT                                dbSNP:rs74575103).
FT                                /FTId=VAR_002487.
FT   VARIANT     291    291       V -> M (in NSHA; Viangchan/Jammu; class
FT                                II; dbSNP:rs137852327).
FT                                /FTId=VAR_002488.
FT   VARIANT     317    317       E -> K (in NSHA; Kalyan/Kerala; class
FT                                III; dbSNP:rs137852339).
FT                                {ECO:0000269|PubMed:1303182}.
FT                                /FTId=VAR_002489.
FT   VARIANT     322    322       Y -> H (in Rehovot; dbSNP:rs137852347).
FT                                {ECO:0000269|PubMed:11112389}.
FT                                /FTId=VAR_020535.
FT   VARIANT     323    323       L -> P (in NSHA; A- type 3; class III;
FT                                dbSNP:rs76723693).
FT                                /FTId=VAR_002490.
FT   VARIANT     335    335       A -> T (in NSHA; Chatham; class III;
FT                                dbSNP:rs5030869).
FT                                /FTId=VAR_002491.
FT   VARIANT     342    342       L -> F (in Chinese-5; dbSNP:rs137852342).
FT                                /FTId=VAR_002492.
FT   VARIANT     353    353       P -> S (in NSHA; Ierapetra; class II;
FT                                dbSNP:rs137852333).
FT                                {ECO:0000269|PubMed:1611091}.
FT                                /FTId=VAR_002493.
FT   VARIANT     363    363       N -> K (in NSHA; Loma Linda; class I;
FT                                dbSNP:rs137852329).
FT                                /FTId=VAR_002494.
FT   VARIANT     385    385       C -> R (in NSHA; Tomah; class I;
FT                                dbSNP:rs137852322).
FT                                /FTId=VAR_002495.
FT   VARIANT     386    386       K -> E (in NSHA; Iowa; class I;
FT                                dbSNP:rs137852320).
FT                                /FTId=VAR_002496.
FT   VARIANT     387    387       R -> C (in NSHA; Guadajalara and Mount
FT                                Sinai; class I; dbSNP:rs137852334).
FT                                {ECO:0000269|PubMed:1611091,
FT                                ECO:0000269|PubMed:9452072}.
FT                                /FTId=VAR_002498.
FT   VARIANT     387    387       R -> H (in NSHA; Beverly Hills; class I;
FT                                dbSNP:rs137852321).
FT                                /FTId=VAR_002497.
FT   VARIANT     393    393       R -> H (in NSHA; Nashville/Anaheim; class
FT                                I; dbSNP:rs137852316).
FT                                {ECO:0000269|PubMed:1536798}.
FT                                /FTId=VAR_002499.
FT   VARIANT     394    394       V -> L (in NSHA; Alhambra; class I;
FT                                dbSNP:rs137852335).
FT                                {ECO:0000269|PubMed:1611091}.
FT                                /FTId=VAR_002500.
FT   VARIANT     396    396       P -> L (in NSHA; Bari; class I).
FT                                {ECO:0000269|PubMed:7959695}.
FT                                /FTId=VAR_002501.
FT   VARIANT     398    398       E -> K (in NSHA; Puerto Limon; class I;
FT                                dbSNP:rs137852325).
FT                                /FTId=VAR_002502.
FT   VARIANT     410    410       G -> C (in NSHA; Riverside; class I;
FT                                dbSNP:rs137852323).
FT                                /FTId=VAR_002503.
FT   VARIANT     410    410       G -> D (in NSHA; Japan; class I;
FT                                dbSNP:rs137852336).
FT                                {ECO:0000269|PubMed:1611091}.
FT                                /FTId=VAR_002504.
FT   VARIANT     416    416       E -> K (in NSHA; Tokyo; class I).
FT                                /FTId=VAR_002505.
FT   VARIANT     439    439       R -> P (in NSHA; Pawnee; class I;
FT                                dbSNP:rs137852337).
FT                                {ECO:0000269|PubMed:1611091}.
FT                                /FTId=VAR_002506.
FT   VARIANT     440    440       L -> F (in NSHA; Telti/Kobe; class I).
FT                                /FTId=VAR_002507.
FT   VARIANT     447    447       G -> R (in NSHA; Santiago de Cuba; class
FT                                I; dbSNP:rs137852317).
FT                                /FTId=VAR_002508.
FT   VARIANT     449    449       Q -> H (in NSHA; Cassano; class II).
FT                                /FTId=VAR_002509.
FT   VARIANT     454    454       R -> C (in NSHA; Chinese-II/Maewo/Union;
FT                                class II; <1% activity;
FT                                dbSNP:rs398123546).
FT                                {ECO:0000269|PubMed:1303180}.
FT                                /FTId=VAR_002510.
FT   VARIANT     454    454       R -> H (in NSHA; Andalus; class I;
FT                                dbSNP:rs137852324).
FT                                /FTId=VAR_002511.
FT   VARIANT     459    459       R -> L (in NSHA; Canton; class II;
FT                                frequent in China; dbSNP:rs72554665).
FT                                /FTId=VAR_002512.
FT   VARIANT     459    459       R -> P (in NSHA; Cosenza; class II;
FT                                dbSNP:rs72554665).
FT                                /FTId=VAR_002513.
FT   VARIANT     463    463       R -> H (in NSHA; Kaiping; class II;
FT                                dbSNP:rs72554664).
FT                                /FTId=VAR_002514.
FT   VARIANT     488    488       G -> V (in NSHA; Campinas; class I).
FT                                /FTId=VAR_002515.
FT   MUTAGEN     171    171       K->Q: Inhibits catalytic activity. Does
FT                                not impair dimerization.
FT                                {ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     171    171       K->R: Inhibits catalytic activity. Does
FT                                not impair dimerization.
FT                                {ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     386    386       K->Q: Impairs dimerization and reduces
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     386    386       K->R: Does not impair dimerization and
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     403    403       K->Q: Impairs dimerization and reduces
FT                                catalytic activity in cells under
FT                                oxidative stress.
FT                                {ECO:0000269|PubMed:24769394}.
FT   MUTAGEN     403    403       K->R: Does not impair dimerization and
FT                                catalytic activity.
FT                                {ECO:0000269|PubMed:24769394}.
FT   CONFLICT     11     11       Q -> H (in Ref. 1; CAA27309, 2; AAA63175
FT                                and 3; AAA52500). {ECO:0000305}.
FT   CONFLICT    435    436       DA -> EP (in Ref. 15; AAA52499).
FT                                {ECO:0000305}.
FT   STRAND       32     37       {ECO:0000244|PDB:2BH9}.
FT   TURN         38     40       {ECO:0000244|PDB:2BH9}.
FT   HELIX        42     46       {ECO:0000244|PDB:2BH9}.
FT   HELIX        48     57       {ECO:0000244|PDB:2BH9}.
FT   STRAND       63     73       {ECO:0000244|PDB:2BH9}.
FT   HELIX        77     84       {ECO:0000244|PDB:2BH9}.
FT   HELIX        85     87       {ECO:0000244|PDB:2BH9}.
FT   HELIX        92     94       {ECO:0000244|PDB:2BH9}.
FT   HELIX        95    103       {ECO:0000244|PDB:2BH9}.
FT   STRAND      105    109       {ECO:0000244|PDB:2BH9}.
FT   HELIX       115    126       {ECO:0000244|PDB:2BH9}.
FT   TURN        127    133       {ECO:0000244|PDB:2BH9}.
FT   STRAND      134    140       {ECO:0000244|PDB:2BH9}.
FT   TURN        144    146       {ECO:0000244|PDB:2BHL}.
FT   HELIX       147    157       {ECO:0000244|PDB:2BH9}.
FT   STRAND      161    163       {ECO:0000244|PDB:2BH9}.
FT   STRAND      165    169       {ECO:0000244|PDB:2BH9}.
FT   HELIX       177    187       {ECO:0000244|PDB:2BH9}.
FT   TURN        188    190       {ECO:0000244|PDB:2BH9}.
FT   HELIX       193    195       {ECO:0000244|PDB:2BH9}.
FT   STRAND      196    198       {ECO:0000244|PDB:2BH9}.
FT   HELIX       201    204       {ECO:0000244|PDB:2BH9}.
FT   HELIX       206    216       {ECO:0000244|PDB:2BH9}.
FT   HELIX       219    221       {ECO:0000244|PDB:2BH9}.
FT   STRAND      222    226       {ECO:0000244|PDB:2BHL}.
FT   TURN        227    229       {ECO:0000244|PDB:2BH9}.
FT   STRAND      230    238       {ECO:0000244|PDB:2BH9}.
FT   HELIX       247    250       {ECO:0000244|PDB:2BH9}.
FT   TURN        251    253       {ECO:0000244|PDB:2BH9}.
FT   HELIX       254    258       {ECO:0000244|PDB:2BH9}.
FT   TURN        259    262       {ECO:0000244|PDB:2BH9}.
FT   HELIX       263    272       {ECO:0000244|PDB:2BH9}.
FT   STRAND      277    280       {ECO:0000244|PDB:2BH9}.
FT   HELIX       281    292       {ECO:0000244|PDB:2BH9}.
FT   HELIX       300    302       {ECO:0000244|PDB:2BH9}.
FT   STRAND      303    309       {ECO:0000244|PDB:2BH9}.
FT   HELIX       317    319       {ECO:0000244|PDB:2BHL}.
FT   HELIX       322    324       {ECO:0000244|PDB:2BH9}.
FT   STRAND      326    328       {ECO:0000244|PDB:2BHL}.
FT   STRAND      336    344       {ECO:0000244|PDB:2BH9}.
FT   TURN        347    351       {ECO:0000244|PDB:2BH9}.
FT   STRAND      353    361       {ECO:0000244|PDB:2BH9}.
FT   STRAND      366    373       {ECO:0000244|PDB:2BH9}.
FT   STRAND      389    397       {ECO:0000244|PDB:2BH9}.
FT   STRAND      399    407       {ECO:0000244|PDB:2BH9}.
FT   TURN        409    411       {ECO:0000244|PDB:2BH9}.
FT   STRAND      414    423       {ECO:0000244|PDB:2BH9}.
FT   TURN        424    426       {ECO:0000244|PDB:2BH9}.
FT   STRAND      427    431       {ECO:0000244|PDB:2BH9}.
FT   HELIX       436    446       {ECO:0000244|PDB:2BH9}.
FT   HELIX       449    451       {ECO:0000244|PDB:1QKI}.
FT   HELIX       455    475       {ECO:0000244|PDB:2BH9}.
FT   STRAND      480    483       {ECO:0000244|PDB:2BH9}.
FT   STRAND      486    488       {ECO:0000244|PDB:2BH9}.
FT   HELIX       490    498       {ECO:0000244|PDB:2BH9}.
SQ   SEQUENCE   515 AA;  59257 MW;  F2B775340640A96F CRC64;
     MAEQVALSRT QVCGILREEL FQGDAFHQSD THIFIIMGAS GDLAKKKIYP TIWWLFRDGL
     LPENTFIVGY ARSRLTVADI RKQSEPFFKA TPEEKLKLED FFARNSYVAG QYDDAASYQR
     LNSHMNALHL GSQANRLFYL ALPPTVYEAV TKNIHESCMS QIGWNRIIVE KPFGRDLQSS
     DRLSNHISSL FREDQIYRID HYLGKEMVQN LMVLRFANRI FGPIWNRDNI ACVILTFKEP
     FGTEGRGGYF DEFGIIRDVM QNHLLQMLCL VAMEKPASTN SDDVRDEKVK VLKCISEVQA
     NNVVLGQYVG NPDGEGEATK GYLDDPTVPR GSTTATFAAV VLYVENERWD GVPFILRCGK
     ALNERKAEVR LQFHDVAGDI FHQQCKRNEL VIRVQPNEAV YTKMMTKKPG MFFNPEESEL
     DLTYGNRYKN VKLPDAYERL ILDVFCGSQM HFVRSDELRE AWRIFTPLLH QIELEKPKPI
     PYIYGSRGPT EADELMKRVG FQYEGTYKWV NPHKL
//
